# Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

> **NCT07172971** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Larry W. Markham** · enrollment: 10 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy (DMD)

## Interventions

- **DRUG:** SGLT-2 inhibitor
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT07172971
- **Lead sponsor:** Larry W. Markham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172971, "Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07172971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*